RICHARD A contact VAN ETTEN

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
    Richard A Van Etten
    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Leuk Lymphoma 54:1151-8. 2013
  2. pmc The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
    Richard A Van Etten
    Division of Hematology Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Haematologica 96:590-601. 2011
  3. ncbi request reprint BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia
    Richard A Van Etten
    Molecular Oncology Research Institute, Division of Hematology Oncology, Tufts Medical Center, Boston, MA 02111, USA
    Cancer Cell 20:3-5. 2011

Research Grants

  1. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    RICHARD VAN ETTEN; Fiscal Year: 2005
  2. INHIBITOR OF THE C ABL TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2002
  3. Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
    RICHARD VAN ETTEN; Fiscal Year: 2007
  4. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    RICHARD VAN ETTEN; Fiscal Year: 2007
  5. Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease
    RICHARD VAN ETTEN; Fiscal Year: 2009
  6. Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease
    Richard A Van Etten; Fiscal Year: 2010
  7. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    Richard A Van Etten; Fiscal Year: 2010
  8. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
  9. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010

Collaborators

Detail Information

Publications3

  1. pmc Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
    Richard A Van Etten
    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Leuk Lymphoma 54:1151-8. 2013
    ..A report summarizing the pertinent advances in MPN has been published separately...
  2. pmc The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
    Richard A Van Etten
    Division of Hematology Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Haematologica 96:590-601. 2011
    ..Finally, the clinical role of the new JAK2- and BCR-ABL1-inhibitors is considered. Much further progress is likely in several of these areas soon...
  3. ncbi request reprint BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia
    Richard A Van Etten
    Molecular Oncology Research Institute, Division of Hematology Oncology, Tufts Medical Center, Boston, MA 02111, USA
    Cancer Cell 20:3-5. 2011
    ..In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors...

Research Grants33

  1. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    RICHARD VAN ETTEN; Fiscal Year: 2005
    ..This knowledge will be valuable for improving the diagnosis and treatment of the Ph-positive leukemias. ..
  2. INHIBITOR OF THE C ABL TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2002
    ..These experiments will yield important new information about the function and regulation of c-Abl and the mode of activation of leukemogenic forms of Abl, and identify new avenues for anti-leukemic therapies. ..
  3. Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
    RICHARD VAN ETTEN; Fiscal Year: 2007
    ..abstract_text> ..
  4. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    RICHARD VAN ETTEN; Fiscal Year: 2007
    ..These studies should generate important new knowledge about the pathogenesis of these diseases that will impact directly on improvements in therapy. ..
  5. Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease
    RICHARD VAN ETTEN; Fiscal Year: 2009
    ..In this proposal, a mouse model of PV will be used to better understand the basic cause of PV, and to test new treatments for the disease, which could lead to better treatments for PV patients. ..
  6. Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative Disease
    Richard A Van Etten; Fiscal Year: 2010
    ..In this proposal, a mouse model of PV will be used to better understand the basic cause of PV, and to test new treatments for the disease, which could lead to better treatments for PV patients. ..
  7. STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE
    Richard A Van Etten; Fiscal Year: 2010
    ..These studies should generate important new knowledge about the pathogenesis of these diseases that will impact directly on improvements in therapy. ..
  8. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
    ..Finally, primary abl-/- fibroblasts (before and after rescue with selected abl constructs) will be used to assess the role of c-abl in growth arrest induced by DNA damage. ..
  9. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..PHS 398/2590 (Rev. 11/07) Page 2 Continuation Format Page Program Director/Principal Investigator (Last, First, Middle): Van Etten R.A./Klingemann H.K. ..